)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Sprint Bioscience
Sprint Bioscience (SPRINT) investor relations material
Sprint Bioscience Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary26 Aug, 2026
Executive summary
No sales revenue reported for Q2 or H1 2026, compared to 13.9 MSEK and 28.0 MSEK in the same periods last year, due to absence of research financing and external cost reimbursements.
Operating loss widened to -16.6 MSEK in Q2 and -30.9 MSEK in H1 2026, mainly from lack of revenue despite reduced costs.
Positive proof-of-concept results in the NNMT program expanded its scope to chronic kidney disease.
Strategic evaluation of the STK25 program completed, maintaining focus on MASH.
New CFO and board member appointed; partnership with Lilly TuneLab announced post-period.
Financial highlights
Q2 2026 net sales: 0 MSEK (13.9 MSEK Q2 2025); H1 2026 net sales: 0 MSEK (28.0 MSEK H1 2025).
Q2 2026 operating result: -16.6 MSEK (-6.8 MSEK Q2 2025); H1 2026: -30.9 MSEK (-11.8 MSEK H1 2025).
Net result after tax: -16.2 MSEK in Q2 (-7.4 MSEK Q2 2025); -29.1 MSEK in H1 (-13.0 MSEK H1 2025).
Cash flow from operations: -14.6 MSEK in Q2 (-12.2 MSEK Q2 2025); -33.0 MSEK in H1 (-18.4 MSEK H1 2025).
Cash and cash equivalents at period end: 93.3 MSEK (24.7 MSEK Q2 2025).
Outlook and guidance
Continued focus on advancing preclinical programs, especially NNMT and DCPS, with growing scientific validation and external interest.
Partnership with Lilly TuneLab expected to accelerate AI-driven drug development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sprint Bioscience
- Strong R&D progress and expanded pipeline offset by lower revenue and increased net loss.SPRINT
Q1 2026 - Record revenue and profit growth fueled by a major asset sale and portfolio optimization.SPRINTQ4 2025
- TREX1 program sold to Gilead for $14M upfront, boosting financials after a loss-making quarter.SPRINTQ3 2025
- Early-stage drug discovery innovator leverages partnerships and a broad portfolio for growth.SPRINTLife Science Summit 2025
- Rights issue completed, VRK1 returned, revenue down, new EDDC partnership for MASH.SPRINTQ2 2025
- Revenue declined and losses widened in Q3, with significant financing uncertainty ahead.SPRINTQ3 2024
- Net sales rose sharply and losses narrowed as research milestones and industry interest increased.SPRINTQ2 2024
- Lower Q1 revenue, cost cuts, and capital raise as VRK1 returns and Petra01 is discontinued.SPRINTQ1 2025
- Revenue up, losses widen, new AML program launched, funding risk persists.SPRINTQ4 2024
Next Sprint Bioscience earnings date
Q3 202611 Nov, 2026
Sprint Bioscience
Next Sprint Bioscience earnings date
Q3 202611 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage